Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity

References

• World Health Organization Obesity and overweight [webpage on the Internet] Geneva World Health Organization 2012 Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html Accessed March 25, 2013
   Google Scholar
• James WP The epidemiology of obesity: the size of the problem J Intern Med 2008 263 4 336 352 18312311
   PubMed Web of Science ®Google Scholar
• Haslam DW James WP Obesity Lancet 2005 366 9492 1197 1209 16198769
   PubMed Web of Science ®Google Scholar
• Overweight, obesity, and health risk National Task Force on the Prevention and Treatment of Obesity Arch Intern Med 2000 160 7 898 904 10761953
   PubMedGoogle Scholar
• Kramer FM Jeffery RW Forster JL Snell MK Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women Int J Obes 1989 13 2 123 136 2663745
   PubMed Web of Science ®Google Scholar
• Ayyad C Andersen T Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999 Obes Rev 2000 1 2 113 119 12119984
   PubMedGoogle Scholar
• Gadde KM Allison DB Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks Circulation 2006 114 9 974 984 16940206
   PubMed Web of Science ®Google Scholar
• Taylor D Withdrawal of Rimonabant – walking the tightrope of 21st century pharmaceutical regulation? Curr Drug Saf 2009 4 1 2 4 19256104
   PubMedGoogle Scholar
• Williams G Withdrawal of sibutramine in Europe BMJ 2010 340 c824 20144986
   PubMed Web of Science ®Google Scholar
• Leblanc ES O’Connor E Whitlock EP Patnode CD Kapka T Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the US Preventive Services Task Force Ann Intern Med 2011 155 7 434 447 21969342
   PubMed Web of Science ®Google Scholar
• Foreyt JP Goodrick GK Gotto AM Limitations of behavioral treatment of obesity: review and analysis J Behav Med 1981 4 2 159 174 7321034
   PubMedGoogle Scholar
• Wadden TA Sternberg JA Letizia KA Stunkard AJ Foster GD Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective Int J Obes 1989 13 Suppl 2 39 46 2613427
   PubMed Web of Science ®Google Scholar
• Gadde KM Kopping MF Wagner HR2nd Yonish GM Allison DB Bray GA Zonisamide for weight reduction in obese adults Arch Intern Med 2012 172 20 1557 1564 23147455
   PubMedGoogle Scholar
• Methods for voluntary weight loss and control NIH Technology Assessment Conference Panel Consensus Development Conference March 30 to April 1, 1992 Ann Intern Med 1993 119 7 Pt 2 764 770 8363212
   PubMedGoogle Scholar
• Long-term pharmacotherapy in the management of obesity National Task Force on the Prevention and Treatment of Obesity JAMA 1996 276 23 1907 1915 8968018
   PubMed Web of Science ®Google Scholar
• Gadde KM Allison DB Combination pharmaceutical therapies for obesity Expert Opin Pharmacother 2009 10 6 921 925 19351275
   PubMed Web of Science ®Google Scholar
• Gadde KM Allison DB Combination therapy for obesity and metabolic disease Curr Opin Endocrinol Diabetes Obes 2009 16 5 353 358 19625958
   PubMedGoogle Scholar
• Dickerson LM Carek PJ Pharmacotherapy for the obese patient Prim Care 2009 36 2 407 415 19501251
   PubMed Web of Science ®Google Scholar
• Qsymia™ (phentermine and topiramate extended-release) [prescribing information] Mountain View, CA VIVIUS, Inc 2012
   Google Scholar
• Rothman RB Baumann MH Appetite suppressants, cardiac valve disease and combination pharmacotherapy Am J Ther 2009 16 4 354 364 19092640
   PubMed Web of Science ®Google Scholar
• Alexander M Rothman RB Baumann MH Endres CJ Brasić JR Wong DF Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis Synapse 2005 56 2 94 99 15729739
   PubMed Web of Science ®Google Scholar
• Adipex-P (phenteramine) [prescribing information] Philadelphia, PA Teva Pharmaceuticals USA, Inc 2012
   Google Scholar
• Verrotti A Scaparrotta A Agostinelli S Di Pillo S Chiarelli F Grosso S Topiramate-induced weight loss: a review Epilepsy Res 2011 95 3 189 199 21684121
   PubMed Web of Science ®Google Scholar
• Bray GA Hollander P Klein S A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity Obes Res 2003 11 6 722 733 12805393
   PubMedGoogle Scholar
• Astrup A Caterson I Zelissen P Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects Obes Res 2004 12 10 1658 1669 15536230
   PubMedGoogle Scholar
• Rosenstock J Hollander P Gadde KM Sun X Strauss R Leung A for OBD-202 Study Group A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients Diabetes Care 2007 30 6 1480 1486 17363756
   PubMed Web of Science ®Google Scholar
• Stenlöf K Rössner S Vercruysse F Kumar A Fitchet M Sjöström L OBDM-003 Study Group Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes Diabetes Obes Metab 2007 9 3 360 368 17391164
   PubMed Web of Science ®Google Scholar
• Eliasson B Gudbjörnsdottir S Cederholm J Liang T Vercruysse F Smith U Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial Int J Obes (Lond) 2007 31 7 1140 1147 17264849
   PubMed Web of Science ®Google Scholar
• Tonstad S Tykarski A Weissgarten J Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension Am J Cardiol 2005 96 2 243 251 16018851
   PubMed Web of Science ®Google Scholar
• Wilding J Van Gaal L Rissanen A Vercruysse F Fitchet M OBES-002 Study Group A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects Int J Obes Relat Metab Disord 2004 28 11 1399 1410 15486569
   PubMed Web of Science ®Google Scholar
• Toplak H Hamann A Moore R Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study Int J Obes (Lond) 2007 31 1 138 146 16703004
   PubMed Web of Science ®Google Scholar
• Richard D Ferland J Lalonde J Samson P Deshaies Y Influence of topiramate in the regulation of energy balance Nutrition 2000 16 10 961 966 11054602
   PubMed Web of Science ®Google Scholar
• Richard D Picard F Lemieux C Lalonde J Samson P Deshaies Y The effects of topiramate and sex hormones on energy balance of male and female rats Int J Obes Relat Metab Disord 2002 26 3 344 353 11896489
   PubMed Web of Science ®Google Scholar
• Picard F Deshaies Y Lalonde J Samson P Richard D Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats Obes Res 2000 8 9 656 663 11225714
   PubMedGoogle Scholar
• Ben-Menachem E Axelsen M Johanson EH Stagge A Smith U Predictors of weight loss in adults with topiramate-treated epilepsy Obes Res 2003 11 4 556 562 12690085
   PubMedGoogle Scholar
• Tremblay A Chaput JP Bérubé-Parent S The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension Eur J Clin Pharmacol 2007 63 2 123 134 17200837
   PubMed Web of Science ®Google Scholar
• Khazaal Y Zullino DF Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes Eur J Clin Pharmacol 2007 63 9 891 892 author reply 893 17632711
   PubMed Web of Science ®Google Scholar
• McElroy SL Arnold LM Shapira NA Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial Am J Psychiatry 2003 160 2 255 261 12562571
   PubMed Web of Science ®Google Scholar
• Turenius CI Htut MM Prodon DA GABA(A) receptors in the lateral hypothalamus as mediators of satiety and body weight regulation Brain Res 2009 1262 16 24 19401161
   PubMed Web of Science ®Google Scholar
• De Simone G Di Fiore A Supuran CT Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? Curr Pharm Des 2008 14 7 655 660 18336311
   PubMed Web of Science ®Google Scholar
• Dodgson SJ Shank RP Maryanoff BE Topiramate as an inhibitor of carbonic anhydrase isoenzymes Epilepsia 2000 41 Suppl 1 S35 S39 10768298
   PubMed Web of Science ®Google Scholar
• Dahl H Norskov K Peitersen E Hilden J Zinc therapy of acetazolamide-induced side-effects Acta Ophthalmol 1984 62 739 745 6391074
   PubMed Web of Science ®Google Scholar
• Husum H Van Kammen D Termeer E Bolwig G Mathé A Topiramate normalizes hippocampal NPY-LI in flinders sensitive line ‘depressed’ rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects Neuropsychopharmacology 2003 28 7 1292 1299 12700690
   PubMed Web of Science ®Google Scholar
• Wilkes JJ Nelson E Osborne M Demarest KT Olefsky JM Topiramate as an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats Am J Physiol Endocrinol Metab 2005 288 3 E617 E624 15536205
   PubMed Web of Science ®Google Scholar
• Kadowaki T Yamauchi T Kubota N Hara K Ueki K Tobe K Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome J Clin Invest 2006 116 7 1784 1792 16823476
   PubMed Web of Science ®Google Scholar
• Gadde KM Allison DB Ryan DH Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial Lancet 2011 377 9774 1341 1352 21481449
   PubMed Web of Science ®Google Scholar
• Bialer M Doose DR Murthy B Pharmacokinetic interactions of topiramate Clin Pharmacokinet 2004 43 12 763 780 15355124
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration July 15, 2010, Advisory Committee Meeting for Phentermine/Topiramate (Qnexa) Silver Spring, MD Division of Metabolism and Endocrinology Products (DMEP) Office of Drug Evaluation II Center for Drug Evaluation and Research, US Food and Drug Administration 2010 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommitee/UCM218824.pdf Accessed March 25, 2013
   Google Scholar
• Gadde KM Yonish GM Foust MS A 24-week randomized controlled trial of VI-0521, a combination weight loss therapy, in obese adults [abstract] Obes Res 2006 14 A17
   Google Scholar
• Allison DB Gadde KM Garvey WT Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP) Obesity (Silver Spring) 2012 20 2 330 342 22051941
   PubMed Web of Science ®Google Scholar
• Garvey WT Ryan DH Look M Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study Am J Clin Nutr 2012 95 2 297 308 22158731
   PubMed Web of Science ®Google Scholar
• Winslow DH Bowden CH DiDonato K McCullough PA A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phetermine/topiramate for the treatment of obstructive sleep apnea in obese adults Sleep 2012 35 11 1529 1539 23115402
   PubMed Web of Science ®Google Scholar
• Hunt S Russell A Smithson WH UK Epilepsy and Pregnancy Register Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register Neurology 2008 71 4 272 276 18645165
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Clinical Briefing Document, Endocrine and Metabolic Drugs Advisory Committee Meeting February 22, 2012 New Drug Application 22580: VI-052 Qnexa (phentermine/topiramate) Silver Spring, MD Food and Drug Administration 2012 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM292315.pdf Accessed March 25, 2013
   Google Scholar
• White WB Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension Am J Hypertens 1999 12 2 Pt 2 50S 55S 10090295
   PubMed Web of Science ®Google Scholar
• LaRoche SM Helmers SL The new antiepileptic drugs: scientific review JAMA 2004 291 5 605 614 14762040
   PubMed Web of Science ®Google Scholar
• Wenzel RG Schwarz K Padiyara RS Topiramate for migraine prevention Pharmacotherapy 2006 26 3 375 387 16503717
   PubMed Web of Science ®Google Scholar